| Literature DB >> 29279252 |
Arthur Bertachi1, Charrise M Ramkissoon2, Jorge Bondia3, Josep Vehí4.
Abstract
Since the 2000s, research teams worldwide have been working to develop closed-loop (CL) systems able to automatically control blood glucose (BG) levels in patients with type 1 diabetes. This emerging technology is known as artificial pancreas (AP), and its first commercial version just arrived in the market. The main objective of this paper is to present an extensive review of the clinical trials conducted since 2011, which tested various implementations of the AP for different durations under varying conditions. A comprehensive table that contains key information from the selected publications is provided, and the main challenges in AP development and the mitigation strategies used are discussed. The development timelines for different AP systems are also included, highlighting the main evolutions over the clinical trials for each system.Entities:
Keywords: Artificial pancreas; Automated insulin delivery; Closed-loop glucose control; Control de glucosa en lazo cerrado; Diabetes mellitus tipo 1; Infusión automática de insulina; Páncreas artificial; Type 1 diabetes mellitus
Mesh:
Substances:
Year: 2017 PMID: 29279252 DOI: 10.1016/j.endinu.2017.10.011
Source DB: PubMed Journal: Endocrinol Diabetes Nutr (Engl Ed) ISSN: 2530-0180 Impact factor: 1.417